[Skip to Navigation]
Views 1,993
Citations 0
Original Investigation
August 26, 2021

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial

Author Affiliations
  • 1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California
  • 2Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus
  • 3Department of Medicine, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
  • 4Department of Internal Medicine, University of Michigan Cancer Center, Ann Arbor
  • 5Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California
  • 6Department of Internal Medicine, University of Kentucky Markey Cancer Center, Lexington
  • 7Department of Internal Medicine, University of Kansas Medical Center, Westwood
  • 8Department of Internal Medicine, University of Nebraska Medical Center, Omaha
  • 9Department of Medicine, University of Virginia Cancer Center, Charlottesville
  • 10Department of Medicine, University of Wisconsin Cancer Center, Madison
  • 11Department of Medicine, Massachusetts General Hospital, Boston
  • 12Department of Medicine, Duke University Medical Center, Durham, North Carolina
  • 13Department of Medicine, Stanford Cancer Center, Palo Alto, California
JAMA Oncol. Published online August 26, 2021. doi:10.1001/jamaoncol.2021.3441
Key Points

Question  Does inhibition of ataxia telangiectasia and Rad3 complement cisplatin-based chemotherapy for metastatic urothelial cancer?

Findings  In this open-label, phase 2 randomized clinical trial, 87 patients with metastatic urothelial cancer received cisplatin with gemcitabine chemotherapy with or without berzosertib, an ataxia telangiectasia and Rad3 inhibitor. The primary end point of the study was progression-free survival; no significant difference was observed and a trend toward inferior survival was observed with the addition of berzosertib.

Meaning  The findings of this trial indicate that the addition of berzosertib does not add to the efficacy of cisplatin and gemcitabine chemotherapy in patients with metastatic urothelial cancer, likely because of added hematologic toxic effects with the combination resulting in substantial dose reductions.


Importance  Preclinical studies suggest that inhibition of single-stranded DNA repair by ataxia telangiectasia and Rad3 (ATR) may enhance the cytotoxicity of cisplatin, gemcitabine, and other chemotherapeutic agents. Cisplatin with gemcitabine remains the standard up-front therapy for treatment in patients with metastatic urothelial cancer.

Objective  To determine whether the use of the selective ATR inhibitor, berzosertib, could augment the activity of cisplatin with gemcitabine.

Design, Setting, and Participants  In a phase 2 randomized clinical trial, 87 patients across 23 centers in the National Cancer Institute Experimental Therapeutics Clinical Trials Network were randomized to receive either cisplatin with gemcitabine alone (control arm) or cisplatin with gemcitabine plus berzosertib (experimental arm). Key eligibility criteria included confirmed metastatic urothelial cancer, no prior cytotoxic therapy for metastatic disease, 12 months or more since perioperative therapy, and eligibility for cisplatin receipt based on standard criteria. The study was conducted from January 27, 2017, to December 15, 2020.

Interventions  In the control arm, cisplatin, 70 mg/m2, was given on day 1 and gemcitabine, 1000 mg/m2, was given on days 1 and 8 of a 21-day cycle. In the experimental arm, cisplatin, 60 mg/m2, was given on day 1; gemcitabine, 875 mg/m2, on days 1 and 8; and berzosertib, 90 mg/m2, on days 2 and 9 of a 21-day cycle.

Main Outcomes and Measures  The primary end point of the study was progression-free survival. The analysis was on all patients who started therapy.

Results  Of the total of 87 patients randomized, 41 patients received cisplatin with gemcitabine alone and 46 received cisplatin with gemcitabine plus berzosertib. Median age was 67 (range, 32-84) years, and 68 patients (78%) were men. Median progression-free survival was 8.0 months for both arms (Bajorin risk-adjusted hazard ratio, 1.22; 95% CI, 0.72-2.08). Median overall survival was shorter with cisplatin with gemcitabine plus berzosertib compared with cisplatin with gemcitabine alone (14.4 vs 19.8 months; Bajorin risk-adjusted hazard ratio, 1.42; 95% CI, 0.76-2.68). Higher rates of grade 3 vs grade 4 thrombocytopenia (59% vs 39%) and neutropenia (37% vs 27%) were observed with cisplatin with gemcitabine and berzosertib compared with cisplatin with gemcitabine alone; consequently, more dose reductions were needed in the experimental arm. Patients in the experimental arm received a median cisplatin dose of 250 mg/m2, which was significantly lower than the median dose of 370 mg/m2 in the control arm (P < .001).

Conclusions and Relevance  The addition of berzosertib to cisplatin with gemcitabine did not prolong progression-free survival relative to cisplatin with gemcitabine alone in patients with metastatic urothelial cancer, and a trend toward inferior survival was observed with this combination. Berzosertib plus cisplatin with gemcitabine was associated with significantly higher hematologic toxicities despite attenuated dosing of cisplatin with gemcitabine.

Trial Registration  ClinicalTrials.gov Identifier: NCT02567409

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words